We hereby submit the Investor Presentation for the Qtr ended 30th June 2026.

असफ(cid:334) हॉ(cid:729)ीटल सबके िलए (cid:738)ा(cid:726) AHL/AO/2026/1340 Date: 07 August 2026 The Listing Department BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Sub: Submission of Investor Presentation for the Quarter Ended 30 June 2026. Ref: Scrip Code: 543943 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Investor Presentation of Asarfi Hospital Limited for the quarter ended 30 June 2026. The aforesaid Investor Presentation is also being made available on the Company's website at www.asarfi.in. Kindly take the above information on record and bring the same to the notice of all concerned. Thanking you. Yours faithfully, For Asarfi Hospital Limited UDAI PRATAP SINGH Managing Director DIN: 08453794 Asarfi Hospital Limited Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673 Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || www.asarfihospital.com Phone: 7808368888, 9234302735 || Email: info@asarfihospital.com 222000+++ YYYeeeaaarrrsss TTTrrruuusssttt ||| QQQuuuaaallliiitttyyy ||| CCCaaarrreee Leading Healthcare Provider in Eastern India Investor Presentation Q1’FY27 Disclaimer Certainmattersdiscussedinthispresentationmaycontainstatementsregardingthecompany'smarketopportunityandbusinessprospectsthatareindividuallyandcollectively forward-looking statements. Such forward-looking statements do not guarantee future performance and are subject to various known and unknown risks, uncertainties, and assumptions that are inherently difficult to predict. These risks and uncertainties encompass, but are not limited to, the performance of the economy, industry trends, competitivelandscape,thecompany'sabilitytosuccessfullyexecuteitsstrategy,technologicaladvancements,changesinmarketpreferences,andexposuretomarketrisks,as well asother potentialrisks. The company's actualresults, levels of activity,performance, or achievements may differ materially and adversely from the results expressed or impliedinthispresentation.Thecompanyassumesnoobligationtoupdateanyforward-lookinginformationcontainedinthispresentation.Anyforward-lookingstatementsand projectionsmadebythirdpartiesincludedinthispresentationarenotendorsedoradoptedbythecompany,andthecompanydisclaimsanyresponsibilityforsuchthird-party statementsandprojections.Youarecautionednottoplaceunduerelianceontheseforward-lookingstatements,whicharebasedonthecurrentviewsandassumptionsofthe Company'smanagementregardingfutureevents. Q1’FY27 Highlights Quarterly Snapshot – Q1’FY27 (YoY) Q1’FY27 Revenue Q1’FY27 EBITDA Q1’FY27 EBITDA Margin Q1’FY27 PAT RRss 4173.05 CCrr ((+3130.2%% Y YooYY)) RRss 193.50 C Crr ( 3(+51.30%% YYooYY)) Rs 1301 C9r.9 (+% 10% YoY) RRss 143.30 CCrr ((3+61.70%% YYooYY)) Vs Rs120 Cr in FY25 Vs Rs120 Cr in FY25 Vs Rs120 Cr in FY25 Vs Rs120 Cr in FY25 Vs Rs 35.7 Cr in Q1’FY26 Vs Rs 7 Cr in Q1’FY26 Vs 19.6% in Q1’FY26 Vs Rs 3.1 Cr in Q1’FY26 Q1’FY27 PAT Margin Q1’FY27 Bed Capacity Q1’FY27 Occupancy* Q1’FY27 ARPOB Super-Specialty Unit Super-Specialty Unit Super-Specialty Unit Rs 130 9C.r0 % (+10% YoY) 285 (vs 250 in Q1’FY26) 59% (vs 64% in Q1’FY26) 23,498 (vs 19,398 in Q1’FY26) Vs Rs120 Cr in FY25 Cancer Unit Cancer Unit Cancer Unit Vs 8.7% in Q1’FY26 65 (vs 65 in Q1’FY26) 56% (vs 42% in Q1’FY26) 31,892 (vs 31,198 in Q1’FY26) * Occupancy is based on effective beds occupied during the period. ** Financials are on Consolidated basis. Quarterly Profit and Loss Summary Standalone Consolidated (₹ in Lakhs) (₹ in Lakhs) Particulars Q1’FY26* Q4'FY26 Q1’FY27 QoQ% YoY% Particulars Q1’FY26* Q4'FY26 Q1’FY27 QoQ% YoY% Revenue from operations 3,566 4,503 4,734 5.1% 32.8% Revenue from operations 3,568 4,524 4,753 5.1% 33.2% Material costs (857) (987) (1,084) 9.8% 26.4% Material costs (857) (987) (1,084) 9.8% 26.4% Employee benefit expenses (578) (686) (786) 14.6% 36.0% Employee benefit expenses (580) (705) (796) 12.9% 37.1% Other expenses (1,428) (2,045) (1,922) -6.0% 34.7% Other expenses (1,431) (2,060) (1,928) -6.4% 34.7% EBITDA 703 786 942 19.9% 33.9% EBITDA 699 772 946 22.5% 35.3% EBITDA Margin % 19.7% 17.4% 19.9% EBITDA Margin % 19.6% 17.1% 19.9% Depreciation and Amortization (296) (274) (313) 14.3% 5.9% Depreciation and Amortization (299) (276) (315) 14.2% 5.3% Other Income 142 67 59 -10.9% -58.2% Other Income 142 64 57 -11.8% -60.0% EBIT 549 578 688 19.0% 25.3% EBIT 541 560 688 22.7% 27.0% EBIT Margin % 15.4% 12.8% 14.5% EBIT Margin % 15.2% 12.4% 14.5% Finance costs (122) (71) (117) 65.8% -4.1% Finance costs (122) (71) (117) 65.8% -4.1% EBT 427 507 571 12.5% 33.6% EBT 420 490 571 16.5% 36.0% Taxes (108) (98) (144) 46.7% 33.9% Taxes (108) (98) (144) 46.7% 33.9% PAT 320 409 427 4.3% 33.5% PAT 312 392 427 8.9% 36.7% PAT Margin % 9.0% 9.1% 9.0% PAT Margin % 8.7% 8.7% 9.0% * Q1’FY26 figures have been restated/reclassified wherever necessary to conform to the current year’s presentation and classification of the financial statements. Quarterly Highlights – Q1’FY27 Financials (Standalone): IPD-OPD Revenues (₹ in lakhs): Revenue Growth YoY EBITDA Margin 3,935 32.8% 19.9% 2,997 to ₹47 Cr in Q1’FY27 in Q1’FY27 (vs ₹35 Cr in Q1’FY26) (vs 19.7% in Q1’FY26) YoYGrowth in IPD Revenues EBIT Margin PAT Margin 14.5% 9.0% Q1'FY26 Q1'FY27 in Q1’FY27 in Q1’FY27 (vs 15.4% in Q1’FY26) (vs 8.9% in Q1’FY26) IPD Revenues OPD Revenues Super-Specialty Hospital Cancer Hospital Department-wise Revenue Mix Q1’FY27: ARPOB ARPOB Cardiology 23,498 ₹31,892 16% General Medicine 23% 23% in Q1’FY27 in Q4’FY26 Neurosciences Medical Oncology (vs ₹19,398 in Q1’FY26) (vs ₹31,198 in Q1’FY26) 5% General Surgery Surgical Oncology 7% Super-Speciality Cancer Unit Paediatrics and 53% Unit Occupancy Rate Occupancy Rate 12% Neonatology Radiation Oncology Orthopaedics 59% 56% 8% 18% 5% Obstetrics and Others* in Q1’FY27 in Q1’FY27 Gynaecology 7% 17% Gastroenterology 6% (vs 64% in Q1’FY26) (vs 42% in Q1’FY26) Others* Key Financial Parameters Over The Period - Standalone 665,3 305,4 437,4 Revenue (₹ in Lakhs) 12,000 +33% 10,000 8,000 6,000 4,000 2,000 Q1'FY26 Q4'FY26 Q1'FY27 307 687 249 EBITDA (₹ in Lakhs) and Margin % 1,200 19.7% 19.9% 17.4% 1,000 Q1'FY26 Q4'FY26 Q1'FY27 945 875 886 EBIT (₹ in Lakhs) and Margin % 1,000 15.4% 800 14.5% 12.8% Q1'FY26 Q4'FY26 Q1'FY27 023 904 724 PAT (₹ in Lakhs) and Margin % 9.0% 9.1% 9.0% Q1'FY26 Q4'FY26 Q1'FY27 Key Financial Parameters Over The Period - Consolidated 996 277 649 EBITDA (₹ in Lakhs) and Margin % 19.9% 1,200 19.6% 17.1% 1,000 Q1'FY26 Q4'FY26 Q1'FY27 145 065 886 EBIT (₹ in Lakhs) and Margin % 1,000 15.2% 14.5% 800 12.4% Q1'FY26 Q4'FY26 Q1'FY27 213 293 724 PAT (₹ in Lakhs) and Margin % 8.7% 8.7% 9.0% Q1'FY26 Q4'FY26 Q1'FY27 865,3 425,4 357,4 Revenue (₹ in Lakhs) 12,000 +33% 10,000 8,000 +5% 6,000 4,000 2,000 Q1'FY26 Q4'FY26 Q1'FY27 Revenue Mix – Q1’FY27 vs Q1’FY26 Super-Specialty Hospital Unit Q1'FY27 YoY Revenue Growth % by Specialty Cardiology 2.9% Cardiology 16% General Medicine General Medicine 23.7% Neurosciences 28.5% Neurosciences Q1’FY27 General Surgery 13.9% General Surgery 7% Total Revenue Paediatrics and Neonatology 38.8% Paediatrics and Neonatology ₹ 37.1 Cr. 12% Orthopaedics 88.1% 8% Orthopaedics Obstetrics and Gynaecology 73.8% 5% Obstetrics and Gynaecology 7% 17% Gastroenterology 48.0% Gastroenterology Others* 74.3% Others* Cardiology 12% General Medicine Revenue Contribution by Growth Drivers 5% 30% Neurosciences Top 3 Specialties 5% Q1’FY26 General Surgery 52% The YoY growth in Neurosciences, Paediatrics & (vs 60% in Q1’FY26) 6% Total Revenue Paediatrics and Neonatology Neonatology, Orthopaedics, Obstetrics & 5% ₹ 28.2 Cr. Orthopaedics Gynaecology,andGastroenterologywasdrivenby: YoY Revenue Growth of 8% 13% Obstetrics and Gynaecology  Higher patient volumes and higher surgical activity. Top 3 Specialties 17% Gastroenterology  Higher OPD-to-IPD conversion. Others*  Expanded consultant services and better OT utilization. *Others Includ [Showing first 8,000 characters — download PDF for full document]